bioRxiv has recently released a preprint discussing a compelling neutralizing anti-SARS-CoV-2 antibody that hinders variants of concern. The authors identified one monoclonal antibody (mAB), the SARS2-38, powerfully neutralizes all SARS-CoV-2 variants of concern tested and protects mice against challenge by multiple SARS-CoV-2 strains. In the preprint, the structural analysis demonstrated that SARS2-38 employs a conserved epitope proximal to the receptor-binding motif.
The author concluded that treatment with or induction of inhibitory antibodies that attach conserved spike epitopes may reduce the loss of potency of therapies or vaccines against emerging SARS-CoV-2 variants; the conserved epitope bound by SARS2-38 thus may be a potential target for antibodies with therapeutic potential.
VanBlargan L, Adams L, Liu Z, Chen RE, Gilchuk P, Raju S, Smith B, Zhao H, Case JB, Winkler ES, Whitener B, Droit L, Aziati I, Shi PY, Creanga A, Pegu A, Handley S, Wang D, Boon A, Crowe JE, Whelan SPJ, Fremont D, Diamond M. A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. bioRxiv [Preprint]. 2021 Apr 26:2021.04.26.441501. doi: 10.1101/2021.04.26.441501. PMID: 33907753; PMCID: PMC8077627.
Bio X Cell has been supplying the research community for over 20 years with in vivo grade antibodies for biomedical research. It is Bio X Cell’s commitment to providing the highest quality monoclonal antibodies at lowest prices for in vitro and in vivo pre-clinical animal studies. Bio X Cell understands the strict quality criteria required for such studies and the financial limitations faced by many researchers.